Immunome, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for IMNM, updated each market day.
IMNM AI Sentiment
AI sees no strong directional signal for Immunome, Inc. stock over the next 10 market days.
Prediction date: Sept. 22, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Immunome, Inc.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Sector
Exchange
Market Cap
$2,717,912,661
Cap Tier
Employees
177
Headquarters
BOTHELL, WA
Listed Since
Oct. 2, 2020
Website
IMNM Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
IMNM Volatility
Immunome, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
